InnoCare Pharma (688428.SH): Apatinib has been approved for listing by the Australian Therapeutic Goods Administration.

InnoCare Pharma (688428.SH) announced that they have recently received notification that the drug Ibrutinib (trade name: Yinuo Kai, HIBRUKA) has been granted marketing approval by the Australian Therapeutic Goods Administration (TGA). Ibrutinib is a novel BTK inhibitor developed by the company with highly selective target specificity, which can effectively avoid adverse reactions caused by off-target effects and significantly improve the safety and efficacy of treatment. Previously, Ibrutinib has been approved in China for the treatment of first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), previously treated CLL/SLL, previously treated relapsed/refractory mantle cell lymphoma (r/rMCL), and previously treated relapsed/refractory marginal zone lymphoma (r/rMZL), all of which are covered by the national medical insurance. In the international market, Ibrutinib has already been approved in Singapore for the treatment of r/rMCL and r/rMZL in adult patients.